GlassScriptPhysician profile
Caroline Agha
NPI 1316170590
$608.63
in general payments reported to CMS, 2019-2025
13 companies · $18.83 in 2025
The $18.83 reported for 2025 was less than what a typical Neuromusculoskeletal Medicine & Omm provider received nationally (typical 2025 total: $119).
See the full distribution for Neuromusculoskeletal Medicine & OMM
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.99 · 2020: $44.70 · 2021: $259 · 2022: $168 · 2024: $47.45 · 2025: $18.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $66.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $66.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $271.98 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $46.45 | 2022-2024 | Ultomiris |
| Sunovion Pharmaceuticals INC. | $44.70 | 2020 | |
| Glaxosmithkline, LLC. | $36.48 | 2024-2025 | Rotarix, Bexsero, Penmenvy |
| Biohaven Pharmaceuticals, INC. | $31.75 | 2021 | |
| Greenwich Biosciences, INC. | $28.59 | 2019 | |
| Sk Life Science, INC. | $26.46 | 2021 | |
| Amneal Pharmaceuticals LLC | $25.16 | 2019 | |
| Csl Behring | $25.01 | 2021 | |
| Acadia Pharmaceuticals INC | $24.43 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.24 | 2019 | |
| Biogen, INC. | $16.35 | 2021 | |
| Allergan, INC. | $14.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Agha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.